Loading...

Samuel Dychter

SchoolVc-academic Affairs
Address9500 Gilman Drive #NULL
La Jolla CA 92093
Phone000-000-NULL
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer. J Ovarian Res. 2020 Aug 31; 13(1):101. Beachler DC, Lamy FX, Russo L, Taylor DH, Dinh J, Yin R, Jamal-Allial A, Dychter S, Lanes S, Verpillat P. PMID: 32867806.
      View in: PubMed   Mentions:    Fields:    
    2. Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design. Future Oncol. 2018 Sep; 14(21):2103-2113. Pujade-Lauraine E, Fujiwara K, Dychter SS, Devgan G, Monk BJ. PMID: 29584456.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    3. Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours. Br J Cancer. 2018 01; 118(2):e3. Infante JR, Korn RL, Rosen LS, LoRusso P, Dychter SS, Zhu J, Maneval DC, Jiang P, Shepard HM, Frost G, Von Hoff DD, Borad MJ, Ramanathan RK. PMID: 29361630.
      View in: PubMed   Mentions: 3     Fields:    
    4. Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours. Br J Cancer. 2018 01; 118(2):153-161. Infante JR, Korn RL, Rosen LS, LoRusso P, Dychter SS, Zhu J, Maneval DC, Jiang P, Shepard HM, Frost G, Von Hoff DD, Borad MJ, Ramanathan RK. PMID: 28949957.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    5. Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. Clin Cancer Res. 2016 06 15; 22(12):2848-54. Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, Tjulandin SA, Gladkov OA, Holcombe RF, Korn R, Raghunand N, Dychter S, Jiang P, Shepard HM, Devoe CE. PMID: 26813359.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCTClinical Trials
    6. Erratum to: Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration. AAPS J. 2015 Nov; 17(6):1523-4. Rosengren S, Dychter SS, Printz MA, Huang L, Schiff RI, Schwarz HP, McVey JK, Drake FH, Maneval DC, Kennard DA, Frost GI, Sugarman BJ, Muchmore DB. PMID: 26340861.
      View in: PubMed   Mentions:    Fields:    
    7. Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration. AAPS J. 2015 Sep; 17(5):1144-56. Rosengren S, Dychter SS, Printz MA, Huang L, Schiff RI, Schwarz HP, McVey JK, Drake FH, Maneval DC, Kennard DA, Frost GI, Sugarman BJ, Muchmore DB. PMID: 25967925.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    8. Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers. Clin Ther. 2014 Feb 01; 36(2):211-24. Dychter SS, Harrigan R, Bahn JD, Printz MA, Sugarman BJ, DeNoia E, Haughey DB, Fellows D, Maneval DC. PMID: 24486335.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCTClinical Trials
    9. Subcutaneous drug delivery: a route to increased safety, patient satisfaction, and reduced costs. J Infus Nurs. 2012 May-Jun; 35(3):154-60. Dychter SS, Gold DA, Haller MF. PMID: 22498485.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    10. Intravenous therapy: a review of complications and economic considerations of peripheral access. J Infus Nurs. 2012 Mar-Apr; 35(2):84-91. Dychter SS, Gold DA, Carson D, Haller M. PMID: 22382792.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    11. Comparison of the tolerability of recombinant human hyaluronidase + normal saline and recombinant human hyaluronidase + lactated ringer's solution administered subcutaneously: A phase IV, double-blind, randomized pilot study in healthy volunteers. Curr Ther Res Clin Exp. 2009 Dec; 70(6):421-38. Dychter SS, Ebel D, Mead TR, Yocum RC. PMID: 24692835.
      View in: PubMed   Mentions: 4     Fields:    
    12. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med. 2006 Nov 07; 145(9):660-4. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK. PMID: 17088579.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCTClinical Trials
    Samuel's Networks
    Concepts (70)
    Derived automatically from this person's publications.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑